HSKA — Heska Share Price
0.000.00%
Last trade - 00:00HealthcareAdventurousMid Cap
- $1.31bn
- $1.28bn
- $257.31m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.14 | ||
| Price to Tang. Book | 6.34 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 5.14 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -3.5% | ||
| Return on Equity | -4.73% | ||
| Operating Margin | -7.56% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 127.45 | 122.66 | 197.32 | 253.74 | 257.31 | 281.46 | 310.88 | 14.75% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -34.38 | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Heska Corporation sells, manufactures, markets and supports diagnostic and specialty products and solutions for veterinary practitioners. The Company’s portfolio includes point-of-care (POC) diagnostic laboratory instruments and consumables, POC digital imaging diagnostic products, local and cloud-based data services, practice information management software (PIMS) and related software and support, reference laboratory testing, allergy testing and immunotherapy, heartworm preventive products, and vaccines. The Company has two segments. The North America segment consists of the United States, Canada and Mexico. The segment also includes the contract manufacturing of vaccines and pharmaceutical products and a small veterinary laboratory. The International segment consists of geographies outside of North America, primarily its operations in Germany, Italy, Spain, France, Switzerland, Australia and Malaysia. The segment includes its PIMS business and veterinary laboratories.
Directors
- Scott Humphrey NEC (50)
- Kevin Wilson PRE (48)
- Catherine Grassman CFO (45)
- Nancy Wisnewski COO (58)
- Christopher Sveen EVP (38)
- Eleanor Baker EVP (36)
- Steven Eyl EVP (55)
- Anthony Providenti EVP (54)
- Robert Antin IND (71)
- Stephen Davis IND (63)
- Mark Furlong IND
- Joachim Hasenmaier IND (60)
- Sharon Larson IND (60)
- David Sveen IND (64)
- Last Annual
- December 31st, 2022
- Last Interim
- March 31st, 2023
- Incorporated
- March 27th, 1997
- Public Since
- July 10th, 1997
- No. of Shareholders
- 177
- No. of Employees
- 808
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 10,913,754
- Address
- 3760 Rocky Mountain Ave, LOVELAND, 80538-7084
- Web
- https://www.heska.com/
- Phone
- +1 9704937272
- Contact
- Jon Aagaard
- Auditors
- Grant Thornton LLP
Upcoming Events for HSKA
Q3 2023 Heska Corp Earnings Release
Similar to HSKA
Accelerate Diagnostics
NASDAQ Capital Market
Adapthealth
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
Agendia NV
NASDAQ Capital Market
Akili
NASDAQ Capital Market
FAQ
What is the Heska share price?
As of Today at 01:09 UTC, shares in Heska are trading at $119.99. This share price information is delayed by 15 minutes.
How has the Heska share price performed this year?
Shares in Heska last closed at $119.99 and the price had moved by +31.18% over the past 365 days. In terms of relative price strength the Heska share price has outperformed the S&P500 Index by +13.7% over the past year.
What are the analyst and broker recommendations for Heska?
The overall consensus recommendation for Heska is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Heska dividend yield?
Heska does not currently pay a dividend.
Does Heska pay a dividend?
Heska does not currently pay a dividend.
When does Heska next pay dividends?
Heska does not currently pay a dividend.
How do I buy Heska shares?
To buy shares in Heska you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Heska?
As of the previous close price of $119.99, shares in Heska had a market capitalisation of $1.31bn.
Where are Heska shares listed?
Here are the trading details for Heska:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: HSKA
What kind of share is Heska?
Based on an overall assessment of its quality, value and momentum Heska is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Heska share price forecast for 2023?
The analyst consensus target price for shares in Heska is $130.00. That is 8.34% above the last closing price of $119.99.
Analysts covering Heska currently have a consensus Earnings Per Share (EPS) forecast of -$0.85 for the next financial year.
Find out moreWhat is the trend in the Heska share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Heska. Over the past six months, its share price has outperformed the S&P500 Index by +60.02%.
As of the last closing price of $119.99, shares in Heska were trading +37.69% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Heska PE Ratio?
The Heska PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $119.99.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Heska?
Heska's management team is headed by:
- Scott Humphrey - NEC
- Kevin Wilson - PRE
- Catherine Grassman - CFO
- Nancy Wisnewski - COO
- Christopher Sveen - EVP
- Eleanor Baker - EVP
- Steven Eyl - EVP
- Anthony Providenti - EVP
- Robert Antin - IND
- Stephen Davis - IND
- Mark Furlong - IND
- Joachim Hasenmaier - IND
- Sharon Larson - IND
- David Sveen - IND